10th Oct 2018 11:47
LONDON (Alliance News) - Life sciences and medicines company MaxCyte Inc on Wednesday said it has dosed the first patient in its phase I trial for MCY-M11.
MCY-M11 is a mesothelin targeting proposed chimeric antigen receptor for the potential use for patients with relapsed or refractory ovarian cancer and peritoneal mesothelioma.
MaxCyte plans to test MCY-M11 on 15 patients with cancer of the ovary, primary peritoneum, fallopian tube, or advanced peritoneal mesothelioma.
Chief Medical Officer Claudio Dansky Ullmann said: "In recent years we have seen tremendous progress in the treatment of some types of cancer, but there remains a significant need to explore novel treatments that may benefit patients."
"Individuals with advanced and relapsed ovarian cancer or peritoneal mesothelioma have limited effective therapeutic options today. MCY-M11 is an exciting new approach with the potential to improve outcomes for these patients. We look forward to the continued progress of this first clinical study."
Shares were untraded Wednesday, last quoted at 238.00 pence each.
Related Shares:
MaxCyte